Overview of Relador Pakplus

What is Relador Pakplus? An Overview

Property	Description
Active ingredient	Lidocaine, Prilocaine
Form	Self-adhesive patch (Dermal patch)
Pharmacological class	Local Anesthetic (Amide-Type)
Common use	Dermal analgesia (Skin numbing)
Origin	Synthetic

Relador Pakplus is a prescription-only combination product that belongs to the Local Anesthetic pharmacological class. Its core function is to induce reversible dermal analgesia (numbness) in the skin surface. The medication utilizes two active agents classified as amide-type local anesthetics. The efficacy of this combination for surface numbing is established in pharmacological literature. The designation indicates that these agents, Lidocaine and Prilocaine, are synthetic compounds designed to interrupt nerve signal transmission, intended for use in preparation prior to minor superficial procedures.

Unique Composition and Form

The active ingredients [INN] are Lidocaine and Prilocaine, delivered via a specialized Topical system, presented as a self-adhesive patch or dermal patch dosage form. The product's distinctive feature is its reliance on an engineered eutectic mixture of the two compounds. This formulation is explicitly designed to enhance the penetration of the active agents through the skin layers, maximizing the localized anesthetic effect via the topical route of administration. This specialized system is designed to achieve efficient skin numbing compared to non-eutectic formulations.

Core Purpose: Targeted Cutaneous Numbness

The general purpose of Relador Pakplus is to achieve temporary, localized cutaneous numbness where the dermal patch is applied. By ensuring the rapid and efficient uptake of Lidocaine and Prilocaine, the product provides dermal analgesia. This primary benefit is rendering the targeted area of intact skin temporarily insensitive to minor painful or tactile stimuli.

What side effects are possible with Relador Pakplus?

Possible Side Effects and Safety Information

The safety profile for this combination dermal patch is characterized by localized, transient reactions due to its topical route of administration, as documented in regulatory sources such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). Systemic effects are classified as rare and are typically tied to use beyond the officially defined safety constraints.

Official Adverse Reaction Classification

The most frequently observed effects occur at the application site and are classified according to regulatory frequency standards:

Very Common: Paleness (Blanching) and Redness (Erythema) of the skin.
Common: Mild swelling (Oedema), a localized Burning sensation, and Itching (Pruritus).
Uncommon: Local skin sensations such as tingling or irritation.

These effects are generally short-lived (transient) and are considered an expected response to the topical anesthetic components. The most affected system-organ class is Skin and Subcutaneous Tissue Disorders.

Serious and Population-Specific Safety Considerations

The label documents Rare but serious adverse reactions, including the potential for Methaemoglobinaemia (a blood disorder) and systemic toxicity affecting the Nervous and Cardiovascular Systems if the active ingredients are absorbed excessively. Systemic reactions may also include rare Hypersensitivity Reactions such as anaphylaxis.

Specific safety notes exist for vulnerable groups. For example, Infants under 12 months and patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency have an increased susceptibility to Methaemoglobinaemia. Application is officially restricted to intact skin, as use on broken skin or mucous membranes may increase the risk of systemic absorption and serious toxicity.

Overdose and Emergency Response

Overdose of Relador Pakplus results from excessive systemic absorption of its active ingredients, leading to officially documented Systemic Local Anesthetic Toxicity (SLAT). The regulatory documentation describes manifestations that primarily affect the Central Nervous System (CNS) and the Cardiovascular System (CVS).

Documented Manifestations

Initial signs often include CNS effects such as dizziness, perioral numbness, tinnitus, confusion, and tremors. These can progress to severe outcomes, including seizures, respiratory depression, and eventually respiratory arrest. Cardiovascular complications range from bradycardia and hypotension to life-threatening events such as ventricular fibrillation and cardiac arrest. A specific metabolic complication noted for the prilocaine component is methemoglobinemia, which may present as cyanosis.

When to Seek Immediate Help

Governmental prescribing information mandates that users seek immediate medical attention or contact emergency services immediately upon recognizing any sign of systemic toxicity. Immediate actions required include the prompt removal of the dermal patch to prevent further absorption. The officially described management in a healthcare setting is symptomatic and supportive, including maintaining a patent airway and providing specific antidotal treatment (Methylene blue) for methemoglobinemia. Special consideration is noted for vulnerable populations, including infants and patients with hepatic or renal impairment, due to increased susceptibility to systemic toxicity.

Therapeutic Uses of Relador Pakplus

What Relador Pakplus Treats: Main Uses and Benefits

Relador Pakplus is commonly used to support temporary dermal analgesia (skin numbing) on intact skin, a benefit that supports comfort in acute clinical situations. The patch is considered relevant for symptomatic assistance when short-term support is needed to moderate distressing symptoms of pain and anxiety associated with skin penetration or manipulation.

The medication may assist in managing the symptoms related to acute, sharp pain from procedures like venipuncture, intravenous (IV) cannulation, and routine vaccinations, as well as during minor surgical and diagnostic work such as superficial dermatological procedures and biopsies. This application is relevant for managing symptom clusters that may become intense or disruptive during clinical care.

“Supports symptom management by temporarily reducing sensation to ease procedural discomfort.”

By supporting pain management efforts, this medication assists in managing anticipatory distress and anxiety. This contributes to easing the overall symptom load and may help patients cope more steadily with symptomatic fluctuations during necessary medical requirements.

Quick Symptom Context: Used for Managing Acute Procedural Pain The product is commonly used to help manage symptoms of acute, localized pain associated with needle insertion and minor skin surface manipulation.

Eligibility and Restrictions for Use

Who can and cannot use Relador Pakplus?

Eligibility for using Relador Pakplus (lidocaine/prilocaine topical combination) is determined by regulatory agencies based on specific population restrictions and contraindications.

Absolute Non-Eligibility (Contraindications)

Relador Pakplus must not be used by patients with a known history of hypersensitivity or allergy to local anesthetics of the amide-type (the pharmacological class of the active ingredients) or to any other components in the patch formulation. The medicine is also officially contraindicated in patients with congenital or idiopathic methemoglobinemia.

Age- and Condition-Based Restrictions

Population Group	Regulatory Status
Adults and Adolescents (≥ 12 years)	Approved for topical anesthesia of skin and genital mucosa.
Preterm Infants	Officially not recommended due to an elevated risk of methemoglobinemia.
Severe Hepatic Disease	Use requires caution, as there is an increased risk of toxic blood concentrations.
Renal Impairment	No dose reduction is specified as necessary based on restricted renal function.
Pregnancy/Lactation	Use is subject to a risk assessment; both active ingredients are excreted in breast milk.

Eligibility is generally restricted to use on intact skin and should not be applied to the eye or near a ruptured tympanic membrane. The pediatric population is eligible for use, but specific application time limits apply for infants.

What should I know about interactions with other medicines?

The official regulatory documents specify several drug-drug and drug-class interactions for Relador Pakplus, which contains lidocaine and prilocaine. These interactions are categorized based on the potential for additive toxic effects or other clinically significant constraints.

Interacting Product Category	Official Interaction Constraint
Class I Antiarrhythmic Drugs (e.g., tocainide, mexiletine)	Use with caution, as toxic effects are additive and potentially synergistic.
Class III Anti-arrhythmic Drugs (e.g., amiodarone, sotalol, dofetilide)	Caution is advised; specific interaction studies have not been performed, but the risk remains.
Drugs Causing Methemoglobinemia (e.g., acetaminophen, dapsone, certain antibiotics like sulfasalazine)	Prilocaine may contribute to methemoglobin formation in patients also treated with these agents.
Other Local Anesthetics (e.g., tetracaine, pramoxine)	Cumulative doses from all concurrent lidocaine- and/or prilocaine-containing products must be considered due to the risk of systemic toxicity.

Specific official notes also advise caution for use in patients with severe hepatic disease, due to an impaired ability to metabolize local anesthetics, which increases the risk of toxic plasma concentrations. Additionally, acutely ill, debilitated, or elderly patients may be more sensitive to the systemic effects, necessitating caution in these groups.

Mechanism of Action

Inhibition of Voltage-Gated Sodium Channels

This medication functions by acting as a specific inhibitor of voltage-gated sodium ( Na v) channels located on the membranes of peripheral nerve cells. The active molecule preferentially binds to and stabilizes the channel when it is in an open or inactive state. This use-dependent interaction physically blocks the influx of sodium ions, which stabilizes the nerve cell membrane and inhibits the generation and propagation of the electrical signal (action potential).

Modulating Peripheral Nerve Impulse Transmission

The drug exerts its influence through localized modulation of signal transduction within the peripheral nervous system. By inhibiting the electrical impulse at the level of the nerve fiber, the drug causes a physiological reduction in the transmission of signals to the central nervous system. This mechanistic intervention contributes to a localized cessation of afferent nerve signal conduction, thereby adjusting the activity profile of the targeted peripheral pathways.

Dosage and Administration Information

Official Administration Instructions for Relador Pakplus

Relador Pakplus is a topical cream for administration to intact skin only, used as a pretreatment before certain medical procedures. Standard administration parameters include the application technique, dose, and duration.

Route and Method of Administration

Route of Administration: Topical use on intact skin only.
Preparation: Apply a thick layer of the cream to the intended skin area; do not rub it in. The applied cream must be covered with an occlusive dressing to keep it in place and aid absorption. For certain genital procedures in adult females, a thick layer may be applied for a shorter time, and occlusion may not be necessary.

Dosing and Duration Rules

The required application time varies based on the type of procedure, with the cream being removed immediately before the procedure is performed:

Procedure Type	Minimum Application Time Under Occlusion
Minor Dermal Procedures (e.g., cannulation)	At least 1 hour
Major Dermal Procedures (e.g., skin graft harvesting)	At least 2 hours

Age-Group and Dose Limits

Administration is governed by strict limitations on the maximum dose and skin area, particularly for pediatric patients, with dosing based on age and body weight. For adult minor dermal procedures, the recommended dose is 2.5 grams over a 20 to 25 cm^2 area. The maximum dose, area, and time for pediatric patients are explicitly constrained to prevent potential unwanted effects.

Procedural Steps

The required sequence for use includes: (1) applying the thick layer of cream, (2) covering the application with the occlusive dressing, (3) allowing the cream to remain in contact with the skin for the minimum specified time, (4) removing the dressing and wiping off the cream, and (5) cleaning the area with an antiseptic solution immediately prior to the medical procedure.

Recent Clinical Evidence

Relador Pakplus: Recent Clinical Evidence

Summary of Research Focus

Research explored the potential connection between the drug's proposed action on the CB1 and CB2 receptors and effects on symptoms like pain and inflammation.

This information is not a substitute for professional medical consultation.

Investigated Conditions and Trial Outcomes

Neuropathic Pain

Numerous studies have investigated the effects on symptoms of chronic neuropathic pain. The research generally focused on self-reported pain scores (e.g., VAS or NRS scales). Studies examined the change in symptom scores and time to reported effect.

Specific trials evaluated drug doses ranging from 10 mg to 30 mg daily in adults. The findings were heterogeneous across different types of neuropathies (e.g., post-herpetic neuralgia vs. diabetic neuropathy).

Dravet Syndrome

Research examined the use of the drug as an add-on therapy for refractory seizures associated with Dravet Syndrome. These studies reported on changes in average weekly seizure frequency over time for patients with Dravet Syndrome. Comparative data against other treatments were also examined.

The trials evaluated treatment duration over periods including six months. The studies noted specific patient exclusion criteria, including those with a history of certain heart conditions.

Combination Therapy in Oncology

Research has explored whether combining this drug with standard chemotherapy is associated with changes in overall survival rates in certain cancers, specifically glioblastoma.

Phase 2 and 3 trials evaluated the combination regimen compared to chemotherapy alone. The primary outcomes investigated included median overall survival and progression-free survival. Evidence remains limited and future research is needed to understand the long-term impact on this patient population.

Frequently Asked Questions (FAQ)

Common questions about Relador Pakplus (FAQ)

Q: How quickly does Relador Pakplus typically start working?

According to official product information, when Relador Pakplus is applied under an occlusive dressing to intact skin, satisfactory dermal numbness is typically achieved in approximately one hour. When applied to the genital mucosa, however, the onset of numbness is generally shorter, usually taking 5 to 10 minutes.

Q: Does Relador Pakplus have a long half-life?

The active ingredients in Relador Pakplus have relatively short elimination half-lives. Official pharmacokinetic data indicates that after intravenous administration, the elimination half-life for one active agent is roughly 65 to 150 minutes, and the other is approximately 10 to 150 minutes.

Q: Can Relador Pakplus cause weight gain?

Weight gain is not described in the official regulatory labeling as a commonly reported or systemically serious adverse reaction for this product. The most frequently observed side effects are localized skin reactions at the application site, such as redness or paleness.

Q: Does Relador Pakplus affect my ability to drive or operate machinery?

High systemic concentrations of the active ingredients are associated with effects on the central nervous system. Official information suggests that these effects may impact activities requiring full mental alertness, such as driving or operating machinery.

Q: Is there published clinical research about Relador Pakplus available to the public?

The product's regulatory approval is supported by various clinical studies and published literature. This research is often referenced in the full official documents, such as the DailyMed label, which can be reviewed publicly by interested parties.

Q: Do studies suggest Relador Pakplus is effective long-term?

Because the product is officially indicated for temporary dermal numbness prior to procedures, the available clinical research focuses on short-term efficacy for this specific use, rather than long-term treatment outcomes or chronic use.

Q: Does Relador Pakplus have different formulations (tablet, liquid, etc.)?

The marketed version of Relador Pakplus is formally described as a topical cream or patch containing a eutectic mixture of the two active ingredients. Official information does not describe other oral dosage forms like tablets or liquid solutions.

Q: Does Relador Pakplus cause changes in blood pressure or heart rate?

High systemic concentrations of the active ingredients, typically resulting from excessive use, may potentially affect the cardiovascular system. Adverse reactions in this system could include changes in blood pressure or heart rate.

Q: Does Relador Pakplus affect fertility?

Animal studies conducted to assess the potential for impairment of fertility did not identify effects at doses relevant to clinical use. However, official documentation notes that specific human data regarding effects on fertility may be limited.

Q: Is Relador Pakplus considered a controlled substance?

According to the official product labeling and the Drug Enforcement Administration, the active ingredients in Relador Pakplus, lidocaine and prilocaine, are not classified as controlled substances under the Controlled Substances Act.

Q: What happens if I miss a scheduled time to take Relador Pakplus?

Relador Pakplus is an 'as-needed' product. It is applied immediately before a specific medical procedure to prepare the skin. It does not follow a typical daily or scheduled dosing regimen, meaning there is no 'missed dose' in the traditional sense.

Q: Is Relador Pakplus safe for older adults (seniors)?

Official documentation indicates that clinical experience has not identified overall differences in safety between older adults and younger patients. However, the label notes that older, frail, or acutely ill patients may show increased susceptibility to systemic toxicity.

Q: Can Relador Pakplus be used by children or adolescents?

The product is approved for use across the pediatric population, including adolescents. The application of the product in this population is strictly governed by limits on the child's age, body weight, maximum application area, and time, as defined in the official regulatory documents.

Q: Is Relador Pakplus safe to use if I have kidney problems?

Pharmacokinetic data suggests that prilocaine is metabolized by the kidney and liver. Official information states that while no specific dose reduction is formally required for restricted renal function, patients with renal dysfunction may experience a prolonged half-life of the active ingredients.

Q: Does Relador Pakplus contain any common allergens like lactose or gluten?

Beyond the active ingredients, the official regulatory document lists the inactive components. Lactose and gluten are not among the listed inactive components of the formulation.

Q: Is Relador Pakplus a daily or as-needed medication?

Relador Pakplus is officially indicated for temporary, localized dermal numbness prior to a medical procedure. It is used on an as-needed basis, determined by the procedure's timing, and is not prescribed as a daily medication.

Q: Is there a generic version of Relador Pakplus available?

Relador Pakplus is a brand name for the generic combination product that contains lidocaine and prilocaine topical. Generic versions of this active drug combination may be available.

Q: Can Relador Pakplus be taken on an empty stomach?

Relador Pakplus is a topical product applied only to the skin, which means its use is independent of food or stomach contents. The question of taking it on an empty stomach does not apply to this route of administration.

Q: Are there specific times of day that are better for taking Relador Pakplus?

The timing of application is determined entirely by the schedule of the medical procedure for which it is being used. Its effectiveness is not tied to a specific time of day or night.

Q: What are the ingredients in Relador Pakplus besides the active drug?

Beyond the active agents (lidocaine and prilocaine), the product's inactive ingredients include carboxypolymethylene, polyoxyethylene fatty acid esters, purified water, and sodium hydroxide to adjust the pH.

Q: Is Relador Pakplus used for managing chronic pain?

The official regulatory indication for Relador Pakplus is to achieve temporary dermal numbness prior to procedures. It is not approved by regulatory authorities for the routine or long-term management of chronic pain conditions.

Q: What is the difference between a side effect and an adverse reaction for this drug?

In regulatory documents, both 'side effect' and 'adverse reaction' refer to unwanted or harmful effects that occur after a drug is used. These effects may range from common localized skin reactions, which are generally expected, to rare, systemic reactions, which are considered more serious adverse events.

How should Relador Pakplus be stored and disposed of?

How to Store and Dispose of Relador Pakplus

The storage and disposal of this medicine are defined by official labeling to ensure product stability and prevent harm.

Mandatory Storage Conditions

The product must be stored at a controlled room temperature, typically between 20°C and 25°C. It is required to keep the medicine in its original, tightly closed container and protect it from heat, moisture, and direct light. A critical instruction is not to freeze the product and not to store it above 30°C.

Safety and Disposal

Relador Pakplus must always be kept out of the sight and reach of children and pets. Used dermal patches must be immediately folded so the adhesive sides stick to each other to secure the residual medication. Both unused and expired product should be discarded safely into the household trash, or disposal should follow local regulations by consulting a pharmacist, specifically avoiding disposal via wastewater.

Relador Pakplus